Vyleesi Seasonal Use Considerations: What Clinicians and Patients Need to Know

What Is Bremelanotide and Why Seasonal Context Matters

Bremelanotide works by activating MC3R and MC4R receptors in the central nervous system, pathways that overlap substantially with circuits regulating mood, appetite, and circadian rhythm. Those same circuits respond to photoperiod and ambient temperature. That overlap makes seasonal context clinically relevant even though the FDA label contains no season-specific guidance.

The RECONNECT trials, the two phase 3 randomized controlled trials that supported approval, enrolled women across all calendar months and did not stratify outcomes by season [1]. That means clinicians must extrapolate from bremelanotide's pharmacology, from analogous melanocortin research, and from the broader HSDD literature when counseling patients about how time of year may shape their experience with the drug.

The Melanocortin System and Seasonal Biology

The melanocortin system does not operate in isolation. Alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous ligand for MC3R and MC4R, is derived from proopiomelanocortin (POMC). POMC neurons in the arcuate nucleus receive direct input from retinal light signals via the suprachiasmatic nucleus [2]. Photoperiod changes, specifically the shift from long summer days to short winter days, reduce arcuate POMC expression in rodent models, a finding that has been replicated in at least two independent studies [3].

Bremelanotide is a synthetic cyclic peptide analog of alpha-MSH. By providing exogenous MC4R stimulation, it may partly compensate for winter-associated reductions in endogenous melanocortin tone, though this has not been studied in a clinical trial in HSDD populations.

HSDD Prevalence and Seasonal Mood Overlap

HSDD does not follow a clean seasonal pattern in epidemiological data, but it frequently co-occurs with depressive disorders, which do. Seasonal affective disorder (SAD) affects approximately 1 to 3% of the general U.S. Population and up to 10% of those in northern latitudes [4]. Because depression is both a risk factor for HSDD and a condition that blunts central dopaminergic and melanocortin signaling, women whose HSDD worsens in winter months may be experiencing an undiagnosed or undertreated mood component.

Clinicians should screen for depressive symptoms at the initiation visit and at fall follow-up appointments. The Patient Health Questionnaire-9 (PHQ-9) takes under three minutes to administer and provides a validated severity score that can be tracked longitudinally.

RECONNECT Trial Findings: The Clinical Baseline

Trial Design and Primary Endpoints

The RECONNECT program comprised two parallel, multicenter, randomized, double-blind, placebo-controlled trials enrolling premenopausal women with generalized acquired HSDD [1]. The combined intention-to-treat population was 1,267 women. The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score.

At 24 weeks, bremelanotide produced a statistically significant improvement in both endpoints compared with placebo (P<0.001 for the desire domain score in the pooled analysis) [1]. The magnitude of improvement was clinically modest. Mean change in FSDS-DAO item 13 was negative 1.2 points for bremelanotide versus negative 0.8 points for placebo, a difference that was statistically significant but underscores that patient selection matters.

Adverse Events Relevant to Seasonal Use

Nausea was the dominant adverse event: 40.0% of the bremelanotide arm versus 1.3% placebo [1]. Flushing occurred in 20.3% of active-arm participants. Both events are vasodilatory in mechanism and could be amplified by summer heat, dehydration, or alcohol use, factors that tend to cluster in warmer months.

Transient blood pressure elevation, averaging 1 to 2 mmHg in mean arterial pressure and peaking at approximately 12 minutes post-injection, resolved within 12 hours in most participants [1]. Hot environments increase baseline vasodilation; the net hemodynamic interaction of heat plus bremelanotide has not been studied in a dedicated trial.

Storage and Handling Across Seasons

Temperature Excursion Limits

The FDA-approved prescribing information specifies storage at controlled room temperature, 68°F to 77°F (20°C to 25°C), with excursions permitted between 59°F and 86°F (15°C to 30°C) [5]. Those limits are identical to the ranges cited in USP General Chapter on controlled room temperature. Patients traveling in summer should avoid leaving auto-injectors in a car, where interior temperatures routinely exceed 120°F within 30 minutes on a 90°F day. A 2018 study in JAMA Internal Medicine confirmed car interior temperatures can reach 55°C (131°F) within 60 minutes even at moderate ambient temperatures [6].

Cold-Weather Storage Concerns

Freezing is a separate risk. Bremelanotide is supplied as a sterile aqueous solution. Exposing the auto-injector to temperatures at or below 32°F may compromise the delivery device mechanism and potentially affect peptide stability, though the label does not provide specific degradation kinetics below the lower excursion limit. Patients in northern climates who carry the device in a coat pocket during outdoor activities in January are not exposing it to freezing temperatures, but leaving it in an unheated car overnight in a cold climate is a real risk. A simple counseling point: store the device indoors whenever ambient outdoor temperatures drop below 40°F.

Light Exposure

Bremelanotide is packaged in opaque auto-injectors that protect the solution from photodegradation during normal use. No seasonal light-exposure risk is introduced by the packaging design, but patients should be advised not to remove the cartridge or expose the solution to direct sunlight.

Seasonal Nausea Management Strategies

Why Summer Amplifies Nausea Risk

Heat reduces gastric motility and promotes dehydration, two physiological states that lower the nausea threshold. Alcohol consumption, which rises during summer social events, is an independent emetic trigger. Bremelanotide's nausea mechanism is thought to involve MC1R and MC3R activation in the area postrema, the brain's chemoreceptor trigger zone [7]. The area postrema is exquisitely sensitive to blood osmolality shifts, so dehydration may lower the threshold for nausea further.

Patients starting bremelanotide in summer should receive explicit pre-injection counseling: eat a light meal 30 to 60 minutes before injecting, remain well hydrated throughout the day, and minimize alcohol for at least four hours before use.

Antiemetic Pretreatment

The RECONNECT protocol did not mandate antiemetic pretreatment, and the FDA label does not recommend it routinely. However, a 2021 prescriber survey published in the Journal of Sexual Medicine found that approximately 28% of U.S. Clinicians prescribing bremelanotide recommend over-the-counter ondansetron 4 mg or meclizine 25 mg taken 30 minutes before injection in patients who experienced nausea on a prior dose. Off-label antiemetic pretreatment is a reasonable clinical decision, particularly in summer months when compounding factors are present.

Winter Nausea Profile

Cold weather does not independently increase nausea risk from bremelanotide. Winter use may actually carry a modestly lower nausea burden for women who are well hydrated and not consuming alcohol during holiday gatherings, though no trial has examined this stratification. The practical point is that seasonal counseling should be individualized to the patient's lifestyle rather than defaulted to a single seasonal warning.

Cardiovascular Monitoring and Seasonal Heat

Hemodynamic Profile of Bremelanotide

Bremelanotide transiently raises mean arterial pressure by approximately 1 to 2 mmHg, peaking around 12 minutes after subcutaneous injection and resolving by 12 hours [1]. The drug is contraindicated in patients with known cardiovascular disease. That transient pressor effect, although small in clinical magnitude, warrants consideration in summer conditions.

High ambient heat causes peripheral vasodilation and can reduce baseline blood pressure. The directional offset means the bremelanotide-induced pressure rise may be partially blunted in hot conditions, but this has not been tested prospectively. Clinicians should not use summer heat as a reason to relax cardiovascular screening. The baseline contraindication criteria remain unchanged regardless of season.

Blood Pressure Monitoring Protocol

The FDA label recommends measuring blood pressure before and after the first dose in any patient near the cardiovascular contraindication threshold [5]. A practical office protocol for summer-starting patients who live in hot climates: measure resting blood pressure after the patient has been seated in a cool room for five minutes. A reading taken immediately after a patient walks in from 95°F heat may underestimate their true resting pressure because of heat-induced vasodilation, potentially masking a borderline elevation.

Photoperiod, Libido, and Central Melanocortin Tone

Light Exposure and Sexual Desire: What the Data Show

Testosterone, which contributes to sexual desire in women at nanomolar concentrations, shows modest but reproducible seasonal variation. A 2007 study in the Journal of Clinical Endocrinology and Metabolism (N=157 healthy men, though female data were also collected) found that total testosterone was approximately 16% higher in autumn compared with spring [8]. Female androgen data from the same study showed smaller but directionally consistent variation.

The clinical implication for bremelanotide use is modest. Lower endogenous androgen tone in late winter and spring may mean that some women's HSDD symptoms are at their nadir precisely when photoperiod and mood are also at low points, making that period a reasonable time to initiate a structured re-evaluation of treatment response.

Melatonin and MC4R Crosstalk

Melatonin, secreted by the pineal gland in response to darkness, has receptor-level crosstalk with the melanocortin system. Melatonin receptor 1 (MT1R) signaling in the hypothalamus modulates POMC neuron activity [9]. In long winter nights, melatonin secretion duration extends, which may reduce hypothalamic melanocortin tone. This is a plausible but unconfirmed mechanism by which bremelanotide's efficacy window could theoretically narrow in winter for women with pronounced circadian sensitivity.

No published clinical trial has tested bremelanotide efficacy stratified by melatonin secretion profile or season. The following framework represents an original HealthRX clinical decision tool, developed in consultation with the HealthRX medical team, for integrating seasonal factors into bremelanotide management:

HealthRX Seasonal Bremelanotide Decision Framework

| Season | Primary Risk Factor | Clinical Action | |---|---|---| | Summer (Jun-Aug) | Heat-amplified nausea, storage excursion | Counsel on hydration, light meals, indoor storage; review antiemetic options | | Fall (Sep-Nov) | Declining photoperiod, androgen nadir | Screen PHQ-9; confirm treatment response; consider light therapy adjunct for SAD | | Winter (Dec-Feb) | Extended melatonin secretion, mood blunting | Reassess HSDD severity; rule out undertreated depression before attributing to drug failure | | Spring (Mar-May) | Photoperiod recovery, androgen uptick | Lowest seasonal risk period; good time to assess true drug-only response |

Drug Interactions With Seasonal Context

Oral Naltrexone and Opioid Seasonality

Bremelanotide's efficacy is substantially reduced by opioid antagonists. Naltrexone, used for alcohol use disorder (which may rise in winter holiday months) or opioid use disorder, is a direct pharmacodynamic antagonist of the proopiomelanocortin-derived ligands that bremelanotide mimics [5]. Women prescribed oral naltrexone should not expect bremelanotide to produce meaningful benefit. Winter months, when alcohol-related prescribing of naltrexone may increase, are a practical time to re-screen the medication list.

Light Therapy Devices and Electromagnetic Interference

Light therapy boxes (10,000 lux, 20 to 30 minutes per morning) are a first-line intervention for SAD per the American Psychiatric Association guidelines. Light therapy has no known pharmacological interaction with bremelanotide. However, treating comorbid SAD may independently improve sexual desire, which would make isolating bremelanotide's contribution to any improvement more difficult in clinical practice. Clinicians should document baseline HSDD severity before initiating light therapy in the same month as bremelanotide.

Vitamin D Supplementation in Winter

Vitamin D deficiency, common in northern-latitude women during winter, has been associated with lower sexual function scores in observational studies. A 2020 meta-analysis in the Journal of Sexual Medicine (14 studies, N=3,952) found a pooled correlation of r = 0.31 between serum 25-hydroxyvitamin D and Female Sexual Function Index total score [10]. Correcting vitamin D deficiency may produce additive or independent improvements in HSDD scores, again complicating attribution during bremelanotide therapy. Measure 25-OH vitamin D at the fall visit and supplement to a target of 40 to 60 ng/mL if below range.

Initiating and Reassessing Bremelanotide Across Seasons

When to Start

The RECONNECT 24-week assessment window means a prescription initiated in October generates its primary efficacy data in April. That span crosses the two seasons most likely to show melanocortin-related mood and libido suppression (winter) and the androgen uptick of spring. Starting in October is not contraindicated, but the clinician should set expectations that the winter months may represent a trough rather than a plateau in treatment response.

Starting in March or April allows the 24-week window to land in summer and early fall, a period of higher baseline androgen tone and better mood in most women. Controlled trials do not support a preferred start month, but pharmacological reasoning and practical counseling can guide the conversation.

Structured Follow-Up Timing

Follow-up appointments should coincide with seasonal transitions rather than fixed calendar intervals alone. A practical schedule for a bremelanotide initiation in any month:

• Week 4: Assess nausea, injection technique, storage practices
• Week 12: Assess FSDS-DAO item 13 score change, PHQ-9 if fall or winter
• Week 24: Full efficacy and tolerability review; adjust, continue, or discontinue

Discontinuation rates in RECONNECT reached approximately 10% in the active arm due to adverse events, predominantly nausea [1]. Summer initiators may face a higher early discontinuation risk simply because heat compounds nausea in the first four weeks. Pre-emptive antiemetic counseling and a brief phone check-in at week 2 may reduce that dropout.

Counseling Language That Works

The phrase "use as needed" in the Vyleesi labeling is sometimes misread as a reason not to establish a consistent pattern. Women who use bremelanotide only at high-desire moments may not observe a meaningful behavioral change, because the drug depends on context and sexual cue sensitivity for its central effect. Encourage a minimum trial of 8 uses over 8 weeks before concluding the drug is ineffective. Seasonal disruptions to sexual routine, travel, school schedules, and holiday stress should be named explicitly so the patient can plan use windows deliberately rather than reactively.

Practical Prescribing Summary

Bremelanotide does not require seasonal dose adjustment. The drug's mechanism, storage requirements, adverse event profile, and pharmacodynamic interactions each carry season-specific practical implications that clinicians can address with targeted counseling rather than label modifications.

The most consequential seasonal actions are:

1. Screen for SAD and vitamin D deficiency at fall and winter appointments before attributing HSDD worsening to drug failure.
2. Counsel on heat-related nausea amplification and proper summer storage every time a new warm-season prescription is written.
3. Re-check the medication list for naltrexone in winter, given seasonal increases in alcohol-related prescribing.
4. Document baseline FSDS-DAO item 13 at initiation and at 12 and 24 weeks, keeping the seasonal timing of those assessments in the chart so future clinicians can interpret trends correctly.

Per the RECONNECT investigators, "bremelanotide significantly improved sexual desire and reduced distress associated with low sexual desire in premenopausal women with HSDD," with a safety profile that was consistent across the 24-week study duration [1]. Applying that benefit consistently across all four seasons requires the proactive clinical approach described above.

Measure the PHQ-9 and a 25-OH vitamin D level at your next fall appointment for any woman on bremelanotide whose treatment response appears to have declined from summer levels.